PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Accelerated Access Collaborative announces first Rapid Uptake Products for NHS

Image


The Accelerated Access Collaborative (AAC) has announced that Roche Diagnostics tests for suspected pre-eclampsia and heart attack have been recognised as ‘transformative’ and have been selected among only seven Rapid Uptake Products for the NHS.
Following the Government’s response to the Accelerated Access Review, the AAC are bringing together senior leadership from the Government, the NHS and the life sciences industry to drive the uptake and adoption of innovation in the NHS, identifying and supporting the innovations that will be most transformative for patients.
Both diagnostic tests have been previously assessed and recommended by the National Institute for Health and Care Excellence (NICE) for use in clinical practice. The Roche Elecsys immunoassay sFlt-1/PlGF ratio test, used with standard clinical assessment and subsequent clinical follow-up, is recommended to help rule-out pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.
The Elecsys Troponin T high?sensitive assay is recommended for the early rule out of non?ST?segment?elevation myocardial infarction (NSTEMI) or heart attack in people presenting to an emergency department with chest pain and suspected acute coronary syndrome.
Both are simple blood tests that can help clinicians quickly decide on the right course of action for patients and their families. The tests also have the potential to alleviate pressure on NHS resources by supporting clinical decision making and focusing efforts where they are most needed.

The AAC have identified 7 high-potential products with a full evidence base already available to the NHS, but with less than expected uptake. These products will now benefit from a joined-up system of support so that innovations that have been shown to be both clinically and cost-effective to the NHS as well as meeting its priorities can be rapidly introduced and scaled within the health service.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026